KRAS and neoplasm: - Inhibition of CT26 KRAS G12C tumours in syngeneic mouse models; durable cure obtained in 8 out of 10 mice. No durable cure observed in CT26 KRAS G12C tumours of immunodeficient mice (i.e., BALB/c nude mice).